1	
2	
3	
4	Factors associated with viral Load re-suppression after enhanced adherence counseling among
5	recipients of care with an Initial high viral load result in RISE-supported facilities in five States in
6	Nigeria
7	Gbenga Benjamin Obasa ^{1*} , Mukhtar Ijaiya ^{1¶} , Ejike Okwor ^{1&} , Babafemi Dare ^{1&} , Franklin Emerenini ^{2*} ,
8	Prince Anyanwu ^{2&} , Adewale Akinjeji ^{2&} , Kate Brickson ^{3¶} , Jennifer Zech ^{4¶} , Yemisi Ogundare ^{1&} , Emmanuel
9	Atuma ^{1&} , Molly Strachan ^{3¶} , Ruby Fayorsey ^{4¶} , Kelly Curran ^{3¶} .
10	
11	
12	
13	¹ Jhpiego, Nigeria
14	² ICAP Global Health, Nigeria
15	³ Jhpiego, Baltimore
16	⁴ ICAP Global Health, New York
17	
18	
19	

20 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

It is made available under a CC-E	3Y 4.0 International license

21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	* Corresponding author
34	E-mail: <u>gbo2105@cumc.columbia.edu</u> (GBO)
35	E-mail: <u>fe2204@cumc.columbia.edu</u> (FE)
36	
37	
38	¶ These authors contributed equally to this work.
39	& These authors also contributed equally to this work.
40	

41

42 Abstract

43	This study explores factors influencing viral re-suppression among 1,607 recipients of HIV care in
44	Nigeria who completed Enhanced Adherence Counseling (EAC) between July 2021 and June 2022. The
45	analysis, part of the Reaching Impact, Saturation, and Epidemic Control (RISE) project, utilized routine
46	program data from 132 health facilities. Results showed a 91% re-suppression rate post-EAC, with age
47	and ART regimen type identified as significant factors. Adolescents (10-19 years) had a higher
48	likelihood of re-suppression, while ROC on second-line regimens exhibited lower resuppression rates.
49	These findings inform programmatic decisions to enhance HIV treatment outcomes in Nigeria.

50 Background

The World Health Organization (WHO) recommends monitoring Viral load (VL) outcomes as the gold 51 standard to measure the effectiveness of antiretroviral therapy (ART) for recipients of HIV care (ROC) 52 [1,2]. In 2021, WHO revised its HIV treatment monitoring algorithm to assist ROC in reaching viral 53 54 suppression and maintaining an undetectable VL with three categories of VL level: unsuppressed 55 (>=1000 copies/mL), suppressed (detected but <1000 copies/mL) and undetectable (VL not detected 56 by test used)[3]. VL is considered unsuppressed when ≥ 1000 copies/ml for ROC undergoing treatment 57 for more than six months. WHO recommends VL testing for ROCs on treatment for more than six 58 months and then routinely every 12 months [1,4]. However, there are reports of low VL suppression rates among ROC living in low- and middle-income countries [5,6]. Poor adherence to HIV treatment is 59 the most common reason for viral non-suppression and can potentially increase the risk of drug 60 61 resistance, HIV treatment failure, and onward HIV transmission [7,8].

63 The WHO recommends Enhanced Adherence Counseling (EAC) for ROC with unsuppressed VL (>=1000 copies/ml) after six months of ART [2]. The EAC sessions lasting between 3–6 months are designed to 64 65 improve adherence, identify possible barriers to treatment, and resolve treatment difficulties [5]. Studies have shown that informing ROC about the risks of an unsuppressed VL result can improve 66 67 treatment adherence [9]. This will reduce the chances of developing resistance mutations, treatment 68 failure, or disease progression to advanced HIV disease [10]. The combination of EAC with routine VL 69 has improved outcomes among people on ART [10-12]. A first-line treatment failure is established 70 when VL suppression is not attained after EAC sessions. Subsequently, switching to second-line 71 treatment is considered as different ART classes are associated with varying adherence thresholds 72 needed to achieve viral suppression and avoid resistance mutations [13].

73

74 Nigeria has the second largest HIV epidemic in the world, with a total of 1.9 million (1.4%) persons (15-75 49 living with HIV as reported by the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) [14–16]. In 76 2020, there were around 1.8 million HIV/AIDs ROC, and about 67% of all people with HIV knew their 77 status, but only 62% were on HIV treatment, of which 44% were estimated to be virally suppressed 78 [16]. This VL suppression is sub-optimal compared to the UNAIDS third 95 target [15,16]. Studies have 79 suggested several factors associated with VL non-suppression, such as poor medication adherence, 80 suboptimal drug selection, and drug resistance [3,5,9]. Therefore, the need to assess the effectiveness 81 of EAC in routine program implementation and determine factors associated with poor VL suppression 82 is essential.

83

This analysis was conducted as part of the Reaching Impact, Saturation, and Epidemic Control (RISE) project, a five-year global project funded by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the US Agency for International Development (USAID). We analyzed factors associated with viral re-suppression for ROC who enrolled and completed all EAC sessions between July 2021 and June

- 88 2022. We analyzed the demographic and clinical characteristics of ROC with unsuppressed VL (>= 1000
- 89 copies/ml) who had completed EAC. This analysis will inform ongoing programmatic and clinical
- 90 decision-making and improve health outcomes for ROC in Nigeria.

91 Methodology

92 Study design

- 93 A descriptive study using routinely collected service delivery data of ROC on ART in 132 RISE-
- supported health facilities from July 2021 to June 2022.

95 **Program Setting and Description**

96 The RISE project has been implemented in 132 facilities across 56 local government areas within five 97 states in Nigeria, beginning in 2019: Adamawa, Akwa Ibom, Cross River, Niger, and Taraba. According 98 to NAIIS data, Akwa Ibom and Rivers have the highest number of HIV/AIDs ROC in Nigeria [15,17]. Akwa 99 Ibom and Cross River states are located in the country's South-South region and have a prevalence rate 100 of 4.8% and 1.8%, respectively [15]. In the northeast, Adamawa and Taraba have HIV prevalence rates 101 of 2.6 and 1.1 %, respectively, while Niger in the north-central zone has a prevalence of 0.9% [15].

102

103 RISE provides EAC for virally unsuppressed ROC enrolled in ART services at supported facilities in 104 alignment with WHO guidelines. EAC is also offered to ROC who receive drugs outside the facility at the 105 community level. Children and adolescents (<15 years) with an unsuppressed VL are also enrolled in 106 the EAC program, with their caregivers attending the EAC sessions to assist with treatment adherence 107 and VL suppression. According to WHO and Nigerian national guidelines, ROC with high VL results 108 requires a repeat test after at least three EAC sessions. Recipients of care with VL results >=1000 109 copies/ml are enrolled into the EAC and closely monitored frequently with a minimum of 10 contacts

monthly for at least three months, which can be extended to a maximum of 6 months to assess adherence level, after which a VL test is carried out post-EAC. The EAC session is designed to help ROC identify the barriers they face in taking their treatment and formulate an adherence plan. Counselors help ROC identify their goals and provide emotional support to help them reach them. After completion of the EAC sessions, if the VL result is <1000 copies/ml post-EAC, the ROC remains on the same ART regimen. If the VL result is >=1000 copies/ml after completion of the EAC sessions, the ROC is switched to a second-line ART regimen.

117 Program data

118 De-identified client-level data from the Lafiya Management Information System (LAMIS), a web-based 119 electronic medical system, was used to identify HIV ROC on ART with VL >= 1000 copies per ml. Client 120 information included in the data set were sex, date of birth, ART start date, days of ART refill, last drug 121 pickup date, ART regimen type, date of VL testing, WHO clinical staging at last visit, tuberculosis (TB) 122 status at last visit, date of commencement of EAC, EAC enrollment, date of last EAC Session and repeat 123 VL result after completion of EAC. Data cleaning was carried out, for instance, by converting the birth 124 date to age and then breaking it down into age-group categories. The variable "duration on ARTV" was 125 derived from the difference between the start date of ART and the date of last drug pickup. Our outcome variable (VL result post-EAC) was then encoded as a binary classification, which indicated 126 127 whether the patient was unsuppressed (VL \geq 1000 copies/ml) or resuppressed (VL detected < 1000 128 copies/ml).

129

130 Study population

The analysis was conducted using data collected as part of the routine implementation of the RISE
project in Nigeria. Data were collected from 132 health facilities in five states: Adamawa, Akwa Ibom,
Cross River, Taraba, and Niger.

134 Inclusion criteria

- 135 All ROC enrolled in HIV care through the RISE project who have received ART for at least six months
- have VL results >=1000 copies/ml and who started and completed EAC sessions (at least three sessions)
- 137 between July 2021 and June 2022.

138 Exclusion criteria

All ROC with no VL result, VL sample collection date, or ROC whose VL result was greater than one year
were excluded. Also, ROC with data outside the selected period with no record of EAC session and
documented post-EAC VL results were excluded.

142 Data analysis

143 Data were analyzed using SAS On-Demand version 9.04. The primary outcome of the analysis was VL 144 suppression (<1000 copies/ml) after the completed EAC session. The analysis variables were sex, age, enrollment settings, clinical staging, TB co-infection, ARV regimen line, and duration on ART. Descriptive 145 146 analyses were carried out to show demographic and clinical characteristics of ROC with unsuppressed VL (>=1000 copies/ml), suppressed but detectable (>=50 to <1000 copies/ml), and undetectable VL 147 148 (<50 copies/ml). In addition, Pearson's Chi-Square was used to compare demographics, clinical 149 characteristics, and VL re-suppression with a p-value of 0.05. Also, the Log binomial regression model 150 was used to report crude and adjusted risk ratios with 95% Confidence Intervals (95% CI) to determine 151 the association between clinical characteristics and VL re-suppression (<1000 copies/ml) on repeat 152 testing, post-EAC.

153 Ethical Statement

This retrospective analysis was conducted with a firm commitment to ethical principles and guidelines.
The medical records were accessed for research purposes on 26th, October 2022. It is crucial to
highlight that rigorous de-identification measures were implemented, ensuring the privacy and

confidentiality of individual participants throughout the study. The research team did not have access
to information that could identify individual participants during any phase of the research, and all data
were anonymized before analysis.

160 The de-identification process involved the removal of any personally identifiable information and

- 161 careful management of indirect identifiers that could potentially lead to participant identification. After
- 162 completing the data analysis, archived samples, and records were securely stored.

163 Ethical Approval

The study received ethical approval from Johns Hopkins School of Public Health Institutional Review Board IRB#24824 "Secondary Data Analysis of HIV Prevention, Care and Treatment Service Delivery Programs in Africa, which explicitly reviewed and approved the de-identification procedures to safeguard participant confidentiality.

168 **Results**

A total of 127,198 ROC were on ART at RISE-supported Health Facilities, and 1607 (1.3%) completed 169 170 EAC between July 2021 and June 2022 and had post-EAC VL results (Table 1). Among these participants, 171 1,054 (66%) were female. The majority, 1,410 (88%), were enrolled in facility settings, and 1,506 (88%) 172 were on a first-line ART regimen at their last visit. Most individuals (95%) were classified as WHO clinical-173 stage 1 at baseline, and 1,557 (97%) were free from TB co-infection. ROC aged 40 and above accounted 174 for 37% (589), while children < 10 years accounted for 7% (114) of ROC included in this analysis. 175 Approximately 22% (361) of the ROC included in this analysis had been on ART for two years or less. The median time taken to complete all recommended EAC sessions was 12 weeks. Over 90% of 176 participants completed all recommended EAC sessions within three months. Following the completion 177 178 of EAC sessions, the median time for collection of a repeat VL test was 8 weeks (Table 1). About 32% of 179 the participants had a post-EAC VL test done after 8 weeks.

180

181	After the completion of EAC, a total of 1,454 individuals (91%) achieved a suppressed VL (<1000
182	copies/ml) (Table 2). Among them, 336 (23%) had VL >=50 - < 1000 copies/ml, and 1,118 (76%) had an
183	undetectable VL. Females comprised 66% of those who achieved VL re-suppression after EAC. The age
184	group of 40 years and above had the highest proportion of individuals with re-suppressed VL, totaling
185	542 (37%), compared to other age groups. In facility settings, 87% of ROC achieved VL re-suppression,
186	totaling 1,267 individuals, while in community settings, 13% achieved re-suppression, comprising 187
187	individuals. The majority of individuals with WHO clinical-stage 1 (91%) attained VL re-suppression after
188	EAC. Additionally, 91% of ROC without TB co-infection achieved suppressed VL after EAC (p<0.001).
189	Furthermore, 1,408 (93%) ROC on the first-line ART regimen achieved VL re-suppression, compared to
190	ROC on second-line ART 46 (45%) (p<0.001). ROC on treatment for more than 3-5 years had a higher
191	proportion of VL re-suppression than those on other durations of antiretroviral therapy (p<0.031). Table
192	2 further details ROC characteristics and VL re-suppression in the RISE program.

- 193
- 194 Table 1. Demographic and clinical characteristics of Recipients of Care (ROC) with unsuppressed VL

195 (>1000 copies/ml of blood) who completed Enhanced Adherence Counselling (EAC).

Characteristics	Ν	(%)
Total	1607	
Gender		
Female	1054	65.59
Male	553	34.41
Age group		
0-9 years	114	7.09

10-19 years	171	10.64			
20-29 years	226	14.06			
30-39 years	507	31.55			
>=40 years	589	36.65			
Enrollment Settings					
Community	197	12.26			
Facility	1410	87.74			
Clinical Staging					
Stage I	1537	95.64			
Stage II	62	3.86			
Stage III	8	0.50			
TB Co-infection					
No	1557	96.89			
Yes	50	3.11			
ART Regimen Line					
First line	1506	93.71			
Second Line	101	6.29			
Duration on ARV					
0-2 years	361	22.46			
3-5 years	550	34.23			
6-10 years	463	28.81			
>10 years	233	14.50			
Time to complete EAC sessions					
Median (IQR)	12 (0-9 weeks)				

It is made available under a C	C-BY 4.0 International license .
--------------------------------	----------------------------------

13–24 weeks	90	5.60	
≥25 weeks	1	0.06	
Time from EAC session	on completion to repeat VL		
Median (IQR)	8 (4-8 weeks)		
<2 weeks	161	10.13	
2-4 weeks	140	8.81	
4-8 weeks	515	32.39	
8-12 weeks	243	15.28	
>=12 weeks	531	33.40	
DTG-based regimens are the recommended first-line ARV drugs			

197 198

Protease inhibitor-based regimens are the recommended second-line ARV drugs

199

200 Table 2: Results showing the relationship between baseline characteristics and VL resuppression

Characteristics	Detectable	VL	Total	Unsuppressed	P value
	and	undetectable	Suppressed	>=1000	
	suppressed	<50 copies/ml	<1000	copies/ml	
	<1000-50		copies/ml		
	copies/ml				
	N (%)	N (%)	N (%)	N (%)	
Total	336	1118	1454	153	
Gender					
Female	219(22.91)	737(77.09)	956 (90.70)	98 (9.30)	0.6742
Male	117(23.49)	381(76.91)	498 (9.05)	55 (9.95)	
Age group					
0-9 years	39(36.79)	67(63.21)	106 (92.98)	8 (7.02)	

	It is made as	vailable under a CC-B	y. Y 4.0 International lice	ense.	
10-19 years	32(22.70)	109(77.30)	141 (82.46)	30 (17.54)	<.0031
20-29 years	45(21.63)	163(78.37)	208 (92.04)	18 (7.96)	
30-39 years	98(21.44)	359(78.56)	457 (90.14)	50 (9.86)	
>=40 years	122(22.51)	420(77.49)	542 (92.02)	47 (7.98)	
Enrollment					
Settings					
Community	20(10.70)	167(89.30)	187 (94.92)	10 (5.08)	
Facility	316(24.94)	951(75.06)	1267 (89.86)	143 (10.14)	<.0233
Clinical Staging					
Stage I	324(23.19)	1073(76.81)	1397 (90.89)	140 (9.11)	
Stage II	11(21.15)	41(78.85)	52 (83.87)	10 (16.13)	0.0047
Stage III	1(20.00)	4(80.00)	5 (62.50)	3 (37.50)	
TB Co-infection					
No	332(23.55)	1078(76.45)	1410 (90.56)	147 (9.44)	<.0001
Yes	4(9.09)	40(90.91)	44 (88.00)	6 (12.00)	
ART Regimen Line	15(32.61)	31(67.39)			
First line	321(22.80)	1087(77.20)	1408 (93.49)	55 (54.46)	<.0001
Second Line	15(32.61)	31(67.39)	46 (45.54)	98 (6.51)	
Duration on ARV					
D-2 years	66(19.64)	270(80.36)	336 (93.07)	25 (6.93)	
3-5 years	102(20.32)	400(79.68)	502 (91.27)	48 (8.73)	<.0259
6-10 years	115(27.64)	301(72.36)	416 (89.85)	47 (10.15)	
>10 years	53(26.50)	147(73.50)	200 (85.84)	33 (14.16)	

202 Factors Associated with VL Re-suppression.

203 In the unadjusted model analysis, only age, enrollment setting, ART regimen line, and ART duration 204 were significantly associated with VL re-suppression (Table 3). ROC in the 10-19 years age band were 205 13% more likely to be re-suppressed compared to the 0-9 years (CRR: 1.13; 95% CI 1.04 to 1.23). 206 Similarly, ROC in the 20 -29 years (CRR: 1.02; 95% CI 0.96 to 1.08), 30-39 years (CRR: 1.04; 95% CI 0.98 207 to 1.11) and >=40 years (CRR: 1.11; 95% CI 0.96 to 1.07) age bands were more likely to be re-208 suppressed; however, these were not statistically significant. ROC enrolled in the facility were 5.6% 209 more likely to be resuppressed post-EAC than those enrolled in community settings (CRR: 1.06; 95% CI 210 1.02 to 1.10). Conversely, ROC on second-line ART regimens were 49% less likely to be re-suppressed 211 when compared to ROC who were on first-line ART regimens at the time of analysis (CRR: 0.49; 95% CI 212 0.39 to 0.60). Our analysis found that the likelihood of re-suppression post-EAC increased with a longer 213 time on treatment: 3-5 years (CRR: 1.02; 95% CI 0.98 to 1.60); 6-10 years (CRR: 1.04; 95% CI 0.99 to 214 1.08); and >10 years (CRR: 1.08; 95% CI 1.02 to 1.15) respectively. ROC who had been on ART treatment 215 for more than 10 years had a statistically significant 8% higher likelihood of re-suppression than ROC 216 who had been on ART treatment for no more than 2 years.

217

Our adjusted model found age group and ART regimen line as the two factors significantly associated with viral re-suppression (Table 3). ROC in the 10-19 years age band were 10% more likely to be resuppressed compared to the 0-9 years (ARR: 1.10; 95% CI 1.01 to 1.19), which was slightly lower than the probability from our bivariate analysis. While all other age bands had a reduced likelihood of resuppression, this was not statistically significant. Notably, there was a 50% reduced likelihood of viral re-suppression among ROC on second-line regimens compared to ROC on first-line regimens (ARR: 0.50; 95% CI 0.41 to 0.62).

225

227 Table 3. Demographic and clinical characteristics associated with resuppression of VL after completion

228 of enhanced adherence counseling

Characteristics	CRR (95% CI)	ARR (95% CI)	P value
Total			
Gender			
Female	reference	reference	
Male	1.0072 (0.9737 -1.0418)	1.0031 (0.9716-1.0357)	0.8472
Age group			
0-9 years	reference	reference	
10-19 years	1.1305 (1.0378 -1.2313) *	1.0958 (1.0101-1.1886)	0.0276
20-29 years	1.0174 (0.9553 - 1.0836)	0.9969 (0.9361-1.0617)	0.9231
30-39 years	1.0431 (0.9836- 1.1063)	0.9948 (0.941-1.0518)	0.8556
>=40 years	1.1061 (0.9608-1.0746)	0.9774 (0.9264-1.0312)	0.4024
Enrollment			
Settings			
Community	reference	reference	
Facility	1.0564 (1.0183 -1.0959)*	1.0088 (0.9725-1.0465)	0.6390
Clinical Staging			
Stage I	reference	reference	
Stage II	1.0837 (0.9705 -1.2101)	1.0759 (0.9687 -1.195)	0.1717
Stage III	1.4543 (0.8500 -2.4880)	1.2497 (0.7671 -2.0361)	0.3707
TB Co-infection			
No	reference	reference	
Yes	1.0291 (0.9278 -1.1414)	1.0353 (0.9469 -1.1319)	0.4461

ART Regimen Line			
First line	reference	reference	
Second Line	0.4871 (0.3934 -0.6032) *	0.5043 (0.4082 -0.6229)	<.0001
Duration on ARV			
0-2 years	reference	reference	
3-5 years	1.0197 (0.9815 -1.0595)	0.9953 (0.959 -1.033)	0.8039
6-10 years	1.0359 (0.9937- 1.0799)	0.9962 (0.9561 -1.0381)	0.8572
>10 years	1.0843 (1.0219 -1.1505) *	1.0017 (0.9461 -1.0605)	0.9543

229 CRR =crude risk ratio; ARR=adjusted risk ratio * = p < 0.05

230

231 Discussion

232 Our study explored the factors associated with VL re-suppression among 1,607 ROCs who completed 233 EAC in RISE-supported facilities across five states in Nigeria. After completing EAC, 91% of participants 234 achieved a suppressed VL post-EAC, with 23% having VL between \geq 50 and < 1000 copies/ml and 76% 235 having an undetectable VL. Factors associated with VL re-suppression were age and ART regimen line. 236 Our rate of re-suppression is similar to results from other studies that showed rates of re-suppression 237 of 90% -95% after EAC [9,13,18]. Re-suppression rates depend on EAC's type, intensity, and 238 documentation [13,19]. Compared to findings from other similar studies, our 91% re-suppression rate 239 was the highest.

240

The demographic and clinical characteristics of the ROC in this study provided further insights into the factors associated with VL re-suppression. Age was found to be associated with VL re-suppression, with ROC aged 10-19 years significantly more likely to be re-suppressed post-EAC. This finding suggests that this age band may be associated with better post-EAC adherence and treatment outcomes. Our results

245 may be explained by the immediate enrollment on Operation Triple Zero (OTZ), intensive follow-up of 246 such children and adolescents, and caregiver involvement in care by the RISE team. Unlike our findings 247 around age, other studies have found that adolescents were less likely to be re-suppressed post-EAC 248 [9,24]. Similarly, previous studies have found that children and adolescents had comparatively lower 249 suppression rates, with a higher probability of viral suppression among older adolescents [25,26]. 250 Alongside poor adherence, this noted sub-optimal suppression among children and adolescents has 251 been attributed to challenges around access to health facilities, satisfaction with healthcare services, 252 and psychosocial factors, including stigma, school-related activities, caregiver status, knowledge, and 253 availability [27-30].

254

255 The overall proportion of ROC with VL re-suppression did not differ between ROC enrolled in health 256 facilities compared to those in the community. Community ART service delivery has been noted to 257 improve ART uptake, retention, and viral suppression [31–33]. However, a study assessing facility and 258 community refill strategies after community enrollment has noted no difference in viral suppression 259 [34]. Moreover, the provision of comprehensive HIV care services in community settings where ROC 260 may have relatively better access to counseling, support, and regular monitoring is effective in 261 increasing HIV treatment coverage, and an optimal combination of both community and facility approaches will be vital in improving treatment outcomes [35]. 262

263

Similar to the enrollment settings above, ROC who had been on ART for over 10 years were significantly more likely to be re-suppressed from our bivariate analysis but not in our multivariate analysis. VL suppression has been generally associated with increasing duration on treatment and adherence [26,36–38]. However, a study conducted in Ethiopia on VL among ROC post-EAC noted that ROCs on ART treatment between 3-5 years were less likely to be re-suppressed, unlike ours [18].

269

270	ART regimen was a significant predictor in our bivariate and multivariate analyses. ROC on second-line
271	ART regimens were less likely to be resuppressed. This could be due to the majority 1,376 (91%) of ROC
272	being on DTG-based first-line regimens per the Nigeria National Treatment Guidelines [39]. DTG-based
273	regimens have been proven to be highly efficacious in achieving virological suppression in ROC
274	[38,40,41]. In addition, the prior viral unsuppressed results may have been due to non-adherence, and
275	with improved adherence following the EAC sessions, we would expect comparatively better viral re-
276	suppression.

277

278 Furthermore, with the introduction and transition of ROC to DTG-based regimens, ROC who had been 279 on second-line regimens may have never benefitted from the new DTG-based regimens or may have 280 been transitioned back to the new DTG-based regimens. However, two studies on virological outcomes 281 post-EAC in Nigeria and Zimbabwe have noted a higher likelihood of viral re-suppression among ROC 282 on second-line ART regimens [2,21]. This has been attributed to possible lower resistance to second-283 line drugs and ROC's "last chance" perception of medically responsive therapy [21]. Moreover, 284 unsuppressed VL post-EAC has been associated with prolonged first-line ART regimen treatment and 285 drug resistance [13].

286

The strength of this study is the use of routine program data, which provides valuable insights into the real-world effectiveness of EAC in Nigeria. However, there are several limitations to consider. First, the data used was cross-sectional, so causality cannot be inferred from the findings. Second, the analysis relied on routine program data, which may be subject to missing or incomplete information. Additionally, the analysis was limited to only those variables that are routinely collected from patients during visits and available in the EMR. We did not measure other potential vital factors that may be

associated with VL re-suppression, such as socioeconomic factors, social support, or mental healthstatus.

295

In conclusion, this study highlights the effectiveness of EAC in promoting VL suppression in routine
program settings, with 91% re-suppression. The findings suggest that EAC can improve adherence to
antiretroviral therapy and achieve the UNAIDS global target of 95% VL suppression. The study also
identified essential factors associated with VL re-suppression, including age and ART regimen type.
These findings have implications for programmatic and clinical decision-making and highlight the need
for tailored interventions.
Acknowledgments.

303

304 **References**

- World Health Organization. The use of antiretroviral drugs for treating and preventing hiv
 infection. 2016.
- Bvochora T, Satyanarayana S, Takarinda KC, Bara H, Chonzi P, Komtenza B, et al. Enhanced
 adherence counselling and viral load suppression in HIV seropositive patients with an initial
- high viral load in Harare, Zimbabwe: Operational issues. PLoS ONE. 2019 Feb;14(2).
- 310 3. The Joint United Nations Programme on HIV/AIDS (UNAIDS). Understanding Fast-Track:
- Accelerating action to end the AIDS epidemic by 2030. 2015.
- World Health Organization. GUIDELINE ON WHEN TO START ANTIRETROVIRAL THERAPY AND
 ON PRE-EXPOSURE PROPHYLAXIS FOR HIV. 2015.

314	5.	Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors
315		Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral
316		Therapy in Uganda, August 2014-July 2015. BMC Infectious Diseases. 2017 May;17(1).
317	6.	Yiltok E, Agada C, Zoakah R, Malau A, Tanyishi D, Ejeliogu E, et al. Clinical profile and viral load
318		suppression among HIV positive adolescents attending a tertiary hospital in North Central
319		Nigeria. Journal of Medicine in the Tropics. 2020;22(2):133.
320	7.	Bonner K, Mezochow A, Roberts T, Ford N, Cohn J. Viral load monitoring as a tool to reinforce
321		adherence: A systematic review. Journal of Acquired Immune Deficiency Syndromes. 2013
322		Sep;64(1):74-8.
323	8.	Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, Ele P, et al. Patient Retention and
324		Adherence to Antiretrovirals in a Large Antiretroviral Therapy Program in Nigeria: A
325		Longitudinal Analysis for Risk Factors. Myer L, editor. PLoS ONE. 2010 May;5(5):e10584.
326	9.	Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al. Factors associated
327		with virological failure and suppression after enhanced adherence counselling, in children,
328		adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS ONE. 2015
329		Feb;10(2).
330	10.	Labhardt ND, Bader J, Lejone TI, Ringera I, Hobbins MA, Fritz C, et al. Should viral load
331		thresholds be lowered?: Revisiting the WHO definition for virologic failure in patients on
332		antiretroviral therapy in resource-limited settings. Medicine. 2016 Jul;95(28):e3985.
333	11.	WHO. world health Organisation. 2016. The Use of Antiretroviral Drugs for treating And
334		Preventing HIV infection guidelines HIV/AIDS Programme.
335	12.	Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Jouquet G, et al. Impact and
336		programmatic implications of routine viral load monitoring in swaziland. Journal of Acquired

- 338 13. Ford N, Orrell C, Shubber Z, Apollo T, Vojnov L. HIV viral resuppression following an elevated
 339 viral load: a systematic review and meta-analysis. Journal of the International AIDS Society.
 340 2019 Nov;22(11).
- 34114.National Agency for the Control of AIDS (NACA). NATIONAL HIV AND AIDS STRATEGIC
- **342** FRAMEWORK 2021-2025. 2022.
- 343 15. Federal Ministry of Health N. Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) 2018:
 344 Technical Report. Abuja; 2019.
- 345 16. Monitoring GA. Country progress report Nigeria. 2020;
- 17. Negedu-Momoh OR, Balogun O, Dafa I, Etuk A, Oladele EA, Adedokun O, et al. Estimating HIV
- 347 incidence in the Akwa Ibom AIDS indicator survey (AKAIS), Nigeria using the limiting antigen
- avidity recency assay. Journal of the International AIDS Society. 2021 Feb;24(2):e25669.
- 18. Diress G, Dagne S, Alemnew B, Adane S, Addisu A. Viral Load Suppression after Enhanced
- 350 Adherence Counseling and Its Predictors among High Viral Load HIV Seropositive People in
- 351 North Wollo Zone Public Hospitals, Northeast Ethiopia, 2019: Retrospective Cohort Study. AIDS
- **352** research and treatment. 2020;2020:8909232.
- 19. Etoori D, Ciglenecki I, Ndlangamandla M, Edwards CG, Jobanputra K, Pasipamire M, et al.
- Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy
 adherence and rationalize second-line switches in Swaziland. Journal of the International AIDS
 Society. 2018 Oct;21(10):e25194.
- 357 20. Ali MW, Musa MS. The effect of mobile phone utilization for enhanced adherence counselling
 358 intervention among persons with HIV. AIDS Care. 2023 Feb 13;1–9.
- 359 21. Awolude OA, Olaniyi O, Moradeyo M, Abiolu J. Virologic Outcomes Following Enhanced360 Adherence Counselling among Treatment Experienced HIV Positive Patients at University

361 College Hospital, Ibadan, Nigeria. International STD Research & Reviews. 2021 Mar 2;10(1 SE-

362 Original Research Article):53–65.

- 363 22. Laxmeshwar C, Acharya S, Das M, Keskar P, Pazare A, Ingole N, et al. Routine viral load
- 364 monitoring and enhanced adherence counselling at a public ART centre in Mumbai, India.
- **365** PLOS ONE. 2020 May 5;15(5):e0232576.
- 366 23. Ukwueze LN, Ifeanyichukwu C, Ifeanyi C, Iroegbu A, Aribike J, Ikeneche NF. Evaluation of
- 367 Enhanced Adherence Counselling among Virally Unsuppressed HIV-Infected Adults on
- 368 Antiretroviral Therapy in Suburban and Metropolitan parts of Delta State , Nigeria. 2021;5(04).
- 369 24. Mhlanga TT, Jacobs BKM, Decroo T, Govere E, Bara H, Chonzi P, et al. Virological outcomes and
- 370 risk factors for non-suppression for routine and repeat viral load testing after enhanced
- adherence counselling during viral load testing scale-up in Zimbabwe: analytic cross-sectional
- 372 study using laboratory data from 2014 to 2018. AIDS Research and Therapy. 2022;19(1):34.
- 373 25. Nasuuna E, Kigozi J, Babirye L, Muganzi A, Sewankambo NK, Nakanjako D. Low HIV viral
- 374 suppression rates following the intensive adherence counseling (IAC) program for children and
- adolescents with viral failure in public health facilities in Uganda. BMC Public Health.
- **376** 2018;18(1):1048.
- Chhim K, Mburu G, Tuot S, Sopha R, Khol V, Chhoun P, et al. Factors associated with viral nonsuppression among adolescents living with HIV in Cambodia: a cross-sectional study. AIDS
 research and therapy. 2018 Nov;15(1):20.
- 380 27. Montalto GJ, Sawe FK, Miruka A, Maswai J, Kiptoo I, Aoko A, et al. Diagnosis disclosure to
 381 adolescents living with HIV in rural Kenya improves antiretroviral therapy adherence and
- immunologic outcomes: A retrospective cohort study. PLOS ONE. 2017 Oct
- **383** 9;12(10):e0183180.

384 28. Eticha T, Berhane L. Caregiver-reported adherence to antiretroviral therapy among HIV

- infected children in Mekelle, Ethiopia. BMC Pediatrics. 2014;14(1):114.
- 386 29. Bikaako-Kajura W, Luyirika E, Purcell DW, Downing J, Kaharuza F, Mermin J, et al. Disclosure of
- 387 HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS
- **388** and behavior. 2006 Jul;10(4 Suppl):S85-93.
- 389 30. Gichane MW, Sullivan KA, Shayo AM, Mmbaga BT, O' Donnell K, Cunningham CK, et al.
- 390 Caregiver role in HIV medication adherence among HIV-infected orphans in Tanzania. AIDS
 391 care. 2018 Jun;30(6):701–5.
- 392 31. Labhardt ND, Ringera I, Lejone TI, Klimkait T, Muhairwe J, Amstutz A, et al. Effect of Offering
- 393 Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to
- 394 Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized
- **395** Clinical Trial. JAMA. 2018 Mar;319(11):1103–12.
- 32. Eshun-Wilson I, Awotiwon AA, Germann A, Amankwaa SA, Ford N, Schwartz S, et al. Effects of
- 397 community-based antiretroviral therapy initiation models on HIV treatment outcomes: A

398 systematic review and meta-analysis. PLOS Medicine. 2021 May 28;18(5):e1003646.

- 399 33. Barnabas R V, Szpiro AA, van Rooyen H, Asiimwe S, Pillay D, Ware NC, et al. Community-based
 400 antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda
- 401 (DO ART): a randomised trial. The Lancet Global health. 2020 Oct;8(10):e1305–15.
- 402 34. Amstutz A, Lejone TI, Khesa L, Kopo M, Kao M, Bresser M, et al. Offering ART Refill Through
- 403 Community Health Workers Versus Clinic-Based Follow-Up After Home-Based Same-Day ART
- 404 Initiation: The VIBRA Cluster-Randomised Clinical Trial. 2021;
- 405 35. Oladele EA, Badejo OA, Obanubi C, Okechukwu EF, James E, Owhonda G, et al. Bridging the HIV
 406 treatment gap in Nigeria : examining community antiretroviral treatment models. 2018;

- 407 36. Tomescu S, Crompton T, Adebayo J, Akpan F, Dauda DS, Allen Z, et al. Factors associated with
 408 viral load non-suppression in people living with HIV on ART in Nigeria: cross-sectional analysis
 409 from 2017 to 2021. BMJ open. 2023 May;13(5):e065950.
- 410 37. van Liere GAFS, Lilian R, Dunlop J, Tait C, Rees K, Mabitsi M, et al. High rate of loss to follow-up
- 411 and virological non-suppression in HIV-infected children on antiretroviral therapy highlights
- the need to improve quality of care in South Africa. Epidemiology and infection. 2021
- **413** Mar;149:e88.
- 414 38. Mehari EA, Muche EA, Gonete KA. Virological Suppression and Its Associated Factors of
- 415 Dolutegravir Based Regimen in a Resource-Limited Setting: An Observational Retrospective
- 416 Study in Ethiopia. HIV/AIDS (Auckland, NZ). 2021;13:709–17.
- 417 39. Federal Ministry of Health Nigeria. National Guidelines for HIV Prevention, Treatment and418 Care. 2020.
- 40. Abudiore O, Amamilo I, Campbell J, Eigege W, Harwell J, Conroy J, et al. High acceptability and
 viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter
 study in Nigeria. PLOS ONE. 2023 May 17;18(5):e0284767.
- 422 41. Nabitaka VM, Nawaggi P, Campbell J, Conroy J, Harwell J, Magambo K, et al. High acceptability
- 423 and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in
- 424 Uganda: A mixed-methods prospective cohort study. PLOS ONE. 2020 May 27;15(5):e0232419.
- 425